Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 10, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- Date of Movement: January 4, 2007
- Previous Holdings: 17,308,251 Ordinary Share ADRs
- New Holdings: 17,140,684 Ordinary Share ADRs
- Average Price: $52.76
- Reason: A movement in the fund.
Directors Dr J P Garnier and Dr M M Slaoui are noted as potentially interested in the shares held in this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the reduction in the US Retirement Savings Plan's ADR holdings on overall insider ownership percentages.
- Confirm the specific nature of the "movement in the fund" that led to the reduction of 167,567 ADRs.
- Review the full list of potential beneficiaries to understand the scope of the directors' indirect interest.